CoreComm Internet

Features

Make this your home page

FDA panel backs first-of-its-kind flu vaccine using mRNA technology

WASHINGTON (AP) — A new kind of flu vaccine moved a step closer to the U. S. market Thursday as federal health advisers recommended approval of the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. The Food and Drug Administration is evaluating Moderna's new shot, dubbed mFlusiva, for older Americans ahead of the winter flu season. Moderna is seeking full approval for the vaccine's use in people ages 50 to 64 — along with authorization for use in those...

Read More
 

----------
Copyright 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

CoreComm is not responsible for content on external sites. Please review the privacy and security policies of each vendor before making online purchases or providing personal information. Forecast Information Provided by AccuWeather.